1620 Investment Advisors Inc. Sells 1,093 Shares of Pfizer Inc. (NYSE:PFE)

1620 Investment Advisors Inc. decreased its holdings in Pfizer Inc. (NYSE:PFE) by 5.7% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 18,091 shares of the biopharmaceutical company’s stock after selling 1,093 shares during the quarter. 1620 Investment Advisors Inc.’s holdings in Pfizer were worth $480,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Sector Gamma AS raised its stake in Pfizer by 40.9% in the fourth quarter. Sector Gamma AS now owns 1,155,000 shares of the biopharmaceutical company’s stock valued at $30,642,000 after buying an additional 335,000 shares during the period. Lakeshore Financial Planning Inc. bought a new stake in Pfizer in the fourth quarter valued at approximately $327,000. Wayfinding Financial LLC bought a new stake in Pfizer in the fourth quarter valued at approximately $214,000. Goodman Financial Corp raised its stake in Pfizer by 5.5% in the fourth quarter. Goodman Financial Corp now owns 432,271 shares of the biopharmaceutical company’s stock valued at $11,468,000 after buying an additional 22,609 shares during the period. Finally, DCF Advisers LLC raised its stake in Pfizer by 49.5% in the fourth quarter. DCF Advisers LLC now owns 51,350 shares of the biopharmaceutical company’s stock valued at $1,362,000 after buying an additional 17,000 shares during the period. Institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

PFE has been the topic of a number of recent research reports. Bank of America reiterated a “neutral” rating and set a $29.00 target price on shares of Pfizer in a research note on Tuesday, December 10th. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. Guggenheim reiterated a “buy” rating on shares of Pfizer in a research note on Tuesday. Citigroup lowered their target price on Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. Finally, Truist Financial lowered their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, December 18th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Trading Down 0.2 %

Shares of PFE stock opened at $26.17 on Friday. The stock’s fifty day moving average price is $26.18 and its two-hundred day moving average price is $27.07. The company has a market cap of $148.29 billion, a PE ratio of 18.56, a P/E/G ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. During the same period in the prior year, the company earned $0.10 EPS. Pfizer’s revenue was up 24.7% compared to the same quarter last year. Equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Insider Activity

In other news, Director Ronald E. Blaylock purchased 19,457 shares of the company’s stock in a transaction dated Thursday, February 13th. The stock was bought at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.06% of the stock is owned by corporate insiders.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.